


RECEIVED



INFORMATION DISCLOSURE STATEMENT
BY APPLICANT(S)
(Use several sheets if necessary)

Sheet 1 of 3

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
<i>F.G</i>	148	4,269,857	5/1981	Tokuda et al.	424	325	
<i>N</i>	149	5,221,746	6/1993	Partis et al.	546	220	
<i>N</i>	150	5,264,356	11/1993	Rohrschneider	435	236	
<i>N</i>	151	5,622,972	4/1997	Bryant et al.	514	315	
<i>N</i>	152	5,703,058	12/1997	Schinazi et al.	514	45	
<i>N</i>	153	6,093,702	7/2000	Malley et al.	514	45	

FOREIGN PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
<i>F.G</i>	154	2,700,267	1/1993	FR	A61K	9/107		
<i>N</i>	155	0 401 194	6/1990	EPO	A61K	31/70		
<i>N</i>	156	0 477 160	9/1991	EPO	C12P	17/04		
<i>N</i>	157	0 691 327	3/1994	EPO	C07C	217/28		
<i>N</i>	158	0 729 747	2/1996	EPO	A61K	7/48		
<i>N</i>	159	WO91/17145	11/1991	PCT	C07D	211/46		
<i>N</i>	160	WO94/04546	3/1994	PCT	C07H	17/02		Abstract
<i>N</i>	161	WO99/29321	6/1999	PCT	A61K	31/445		
<i>N</i>	162	WO99/40916	8/1999	PCT	A61K	31/445		

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

<i>F.G</i>	163	Acosta, et al., "Agents for Treating Human Immunodeficiency Virus Infection," Am. J. Hosp. Pharm., Vol. 51, September 15, 1994, pp. 2251-2287
<i>N</i>	164	Tennant, et al., "Animal Models in the Preclinical Assessment of Therapy for Viral Hepatitis," Antiviral Therapy, Vol. 1, (Suppl. 4), 1996, pp. 47-52
<i>N</i>	165	Sachs, "Antiretroviral Chemotherapy of Human Immunodeficiency Virus Infections Other Than with Azidothymidine," Arch. Inter. Med., Vol. 152, March 1992, pp. 485-501

EXAMINER

Fariba Chashghaei

DATE CONSIDERED

8/30/01

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED

JUL 26 2001

TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT

BY APPLICANT(S)

(Use several sheets if necessary)

Sheet 2 of 3



F.G	166	Gasparini, et al., "Clinical Importance of the Determination of Tumor Angiogenesis in Breast Carcinoma: Much More Than a New Prognostic Tool," Journal of Clinical Oncology, Vol. 13, No. 3, March 1995, pp. 765-782
"	167	Bruyneel, et al. "Effect of Glycosylation Inhibitors on N-Glycosylpeptides and on Invasion of Malignant Mouse MO ₄ Cells in Vitro," Journal of Cell Science, Vol. 95, 1990, pp. 279-286
"	168	Jacob, "Glycosylation Inhibitors in Biology and Medicine," Current Opinion in Structural Biology, No. 5, 1995, pp. 605-611
"	169	Senuma, et al., "Highly Effective Resolution of 1,3-Dibenzyl-6-hydroxy-3,3a,6,6a-tetrahydro-1H-furo[3,4-d]imidazole-2,4-dione, an Intermediate for Biotin, with Optically Active Amines and Reutilization of the Unwanted Epimer," Chem. Pharm. Bull., Vol. 38, No. 4, 1990, pp. 882-887
"	170	Zitzmann, et al., "Imino Sugars Inhibit the Formation and Secretion of Bovine Viral Diarrhea Virus, a Pestivirus Model of Hepatitis C Virus: Implications for the Development of Broad Spectrum Anti-Hepatitis Virus Agents," PNAS, Vol. 96, No. 21, October 12, 1999, pp. 11878-11882
"	171	Jacob, et al., "Iminosugar alpha-Glucosidase Inhibitors as Drugs and Pro-Drugs for Treatment of HIV Infections," Washington Book of Abstracts, 208th ACS National Meeting, August 21-25, 1994, one page
"	172	Rusconi, et al., "Inhibition of Human Immunodeficiency Virus Type I Replication in Cytokine-Stimulated Monocytes/Macrophages by Combination Therapy," Journal of Infectious Diseases, Vol. 170, 1994, pp. 1361-1366
"	173	Goss, et al., "Inhibitors of Carbohydrate Processing: A New Class of Anticancer Agents," Clinical Cancer Research, Vol. 1, September 1995, pp. 935-944
"	174	Isom, et al., "Molecular Pathology of Human Oncogenic Viruses," Cellular and Molecular Pathogenesis, Chapter 14, 1996, pp. 341-387
"	175	Platt, et al., "Modulation of Cell-Surface Transferrin Receptor by the Imino Sugar N-butyldeoxynojirimycin," 1992, Eur. J. Biochem., Vol. 208, pp 187-193
"	176	Kawakami, et al., "Monoclonal Antibodies with Affinity to Self-Complementary Left-Handed DNA Containing Cyclonucleosides with High Anti Conformation," 1994, Nucleosides & Nucleotides, Vol. 13(1-3), pp. 421-427
"	177	Dicato, et al., "Multidrug Resistance: Molecular and Clinical Aspects," 1997, Cytokines, Cellular & Molecular Therapy, Vol. 3, No. 2, pp. 91-100
"	178	Ratner, et al., "Mechanism of Action of N-Butyl Deoxynojirimycin in Inhibiting HIV-1 Infection and Activity in Combination with Nucleoside Analogs," AIDS Research and Human Retroviruses, Vol. 9, No. 4, 1993, pp. 291-297
"	179	Myers, "New Antiretroviral Agents in the Clinic," Reviews of Infectious Diseases, Vol. 12, No. 5, September/October 1990, pp. 944-950
"	180	Yangco, et al., "Pilot Safety and Efficacy of Combination SC-48334 (N-Butyl-Deoxynojirimycin (NB-DNJ) and Zidovudine (ZDA) in Symptomatic HIV-1 Infected Patients with ≥ 200 - ≤ 500 CD4 Cells/mm ³ ," Abstracts of the 1st National Conference on Human Retroviruses, Session 86, Abstract No. 574, p. 160
"	181	Mitts, et al., "The Reaction of Glucose with Some Amines," Journal of the American Chemical Society, Vol. 66, March 1944, pp. 483-486

EXAMINER *Fariba Ghashghaee*


DATE CONSIDERED *8,30,01*

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED

JUL 26 2001

TECH CENTER 1600/2900



INFORMATION DISCLOSURE STATEMENT
BY APPLICANT(S)
(Use several sheets if necessary)

Sheet 3 of 3

APPLICANT

Richard A. Mueller et al.

FILING DATE

February 12, 1999

GROUP

1614

F.G	182	Fischl, et al., "The Preliminary Efficacy and Safety of N-Butyl-Deoxynojirimycin (SC-48334), an alpha-Glucosidase I Inhibitor, in Combination with Zidovudine (ZDA)," International Conference on AIDS, Berlin, June 6-11, 1993, one page
//	183	Fiume, et al., "Targeting of Antiviral Drugs to the Liver Using Glycoprotein Carriers," Advanced Drug Delivery Reviews, Vol. 14, 1994, pp. 51-65
//	184	Mutchnick, et al., "Thymosin α , Treatment of Chronic Hepatitis B: A Multicenter, Randomized, Placebo-Controlled Double Blind Study," April 1995, AASLD, A1127, one page
//	185	Jones, et al., "Use of the Topliss Scheme for the Design of More Effective Chelating Agents for Cadmium Decorporation," Chem. Res. Toxicol., Vol. 1, 1988, pp. 234-237
//	186	Karrer, et al., "Zur Kenntnis der Reduktionsprodukte aus Aromatischen Aminen und Zuckern," 1935, p. 1338-1340

EXAMINER

Fariba Ghoshghare

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED

JUL 26 2001

TECH CENTER 1600/2900